AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04725591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabeloop Software (Model predictive control)
Description: Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study NCT06680960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk stabilisation exercises
Description: This exercise program includes aerobic exercise, resistance exercise and trunk stabilisation training for eight weeks.
Study NCT06680960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory exercises
Description: This exercise program includes aerobic exercise, resistance exercise and respiratory exercise training for eight weeks.
Study NCT04725591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Declaration of meals
Description: Patient inputs related to meals
Study NCT04725591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No declaration of meals
Description: No patient inputs related to meals
Study NCT04725591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote monitoring (Telemedicine)
Description: Remote follow up by care health providers team
Study NCT04725591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring (Telemedicine)
Description: Remote follow up by care health providers team
Study NCT05536713 — intervention group
Intervention type: DEVICE
Intervention: Guardant SHIELD blood-based colorectal cancer screening test
Description: The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
Study NCT05332067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe
Study NCT05332067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
Study NCT05794152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized breakfast
Description: Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
Study NCT05794152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized snack
Description: Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
Study NCT05794152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized lunch
Description: Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
Study NCT04395599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.
Description: Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
Study NCT05916833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypopressive breathing
Description: Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
Study NCT05916833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noble technique
Description: Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
Study NCT04954287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA1 low dose
Description: see arm/group description
Study NCT04954287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA1 high dose
Description: see arm/group description
Study NCT04167969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots
Description: Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
Study NCT04167969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Imaging will be performed using the GE Signa PET/MRI.
Study NCT04167969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and urine sampling
Description: Staff will perform the IV blood draws and collect urine samples
Study NCT04167969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection
Description: Surgery will be performed within 24 h of the third PET/MRI scan.
Study NCT05449119 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study NCT05449119 — intervention group
Intervention type: OTHER
Intervention: Body Mass Index (BMI)
Description: Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
Study NCT05449119 — intervention group
Intervention type: OTHER
Intervention: 24-hour food and beverage record
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study NCT05449119 — intervention group
Intervention type: OTHER
Intervention: Mini Nutritional assessment (MNA)
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study NCT05449119 — intervention group
Intervention type: OTHER
Intervention: Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study NCT05449119 — intervention group
Intervention type: OTHER
Intervention: Measurement of sensorimotor functions
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study NCT05449119 — intervention group
Intervention type: OTHER
Intervention: Measurement of cognitive functions
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study NCT04878341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
Study NCT04878341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
Study NCT04066751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivacaftor
Description: Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
Study NCT04066751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor
Description: Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
Study NCT04989322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W
Study NCT04989322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg daily
Study NCT04989322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 Q3W
Study NCT04989322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 Q3W
Study NCT05790941 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost and Minoxidil
Description: Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
Study NCT05790941 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Latanoprost and Minoxidil
Description: Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
Study NCT05365529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
Study NCT05365529 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
Study NCT06434857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training in older adults with mild or non existent cognitive impairment
Description: Strength training program applied to strength training group
Study NCT06434857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal excercise in older adults with mild or non existent cognitive impairment
Description: Multimodal exercise program applied to multimodal exercise group
Study NCT05365607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare
Description: A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
Study NCT05365607 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NightWare
Description: NightWare device will not deliver an intervention (i.e., no vibration)
Study NCT05751200 — intervention group
Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.
Study NCT06103734 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Zavegepant 10 mg
Description: 4 doses of zavegpant 10 mg intranasal spray device
Study NCT06103734 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Control 1
Description: 3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
Study NCT06103734 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Control 2
Description: 3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
Study NCT06479018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Venous blood sampling will be carried out for each patient included in the study.
Study NCT06479018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid bubble sampling
Description: Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.
Study NCT06479018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutaneous biopsy
Description: At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
Study NCT05872321 — intervention group
Intervention type: OTHER
Intervention: Complication
Description: whether or not complications occur
Study NCT05128305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine1 and traditional Chinese medicine 2
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Study NCT05128305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: traditional Chinese medicine1 and traditional Chinese medicine 2
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Study NCT05527483 — intervention group
Intervention type: DRUG
Intervention: [68Ga]PSMA
Description: Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
Study NCT05527483 — intervention group
Intervention type: DRUG
Intervention: Flourine-18 [F-18] Sodium Fluoride (NaF)
Description: Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
Study NCT06322940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 250 mL serving size, 3.25% fat content
Description: Milk
Study NCT06322940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 175 g serving size, ≥2% fat content
Description: Yogurt
Study NCT06322940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50 g serving size, ≥28% fat content
Description: Cheese
Study NCT06043154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding
Description: Clinical and biological measurements, blood and stool sample collection
Study NCT05548283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta-lactam antibiotic
Description: Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
Study NCT05548283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aminoglycoside
Description: Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
Study NCT05527483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
Study NCT05951101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith LAA Occlusion System
Description: LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
Study NCT05923255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）
Description: Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
Study NCT05923255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRH（Traditional Laparoscopic Right Hemicolectomy）
Description: Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
Study NCT05223192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Entrainment with Ocean Disc Intervention
Description: The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
Study NCT05481502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: 3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
Study NCT05481502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
Study NCT05481502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow sample
Description: If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
Study NCT04756050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
Study NCT04756050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine HCl % 2 injectable solution
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
Study NCT04756050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline amp 0.5mg
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
Study NCT04756050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Supraclavicular Block Corner pocket approach
Description: The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
Study NCT04756050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach
Description: The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
Study NCT04756050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Supraclavicular Block multi approach
Description: The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
Study NCT04756050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagraphma muscle evaluation with ultrasound
Description: All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus.
Study NCT05264337 — intervention group
Intervention type: OTHER
Intervention: Self-reported lymphedema
Description: Lymphedema as reported by LymQOL questionnaire.
Study NCT05231369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChulaCov19 BNA159 mRNA vaccine
Description: ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
Study NCT05264337 — intervention group
Intervention type: OTHER
Intervention: Dielectric constant ratio
Description: Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
Study NCT05264337 — intervention group
Intervention type: OTHER
Intervention: Limb volume
Description: Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
Study NCT06269874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: microvascular function assessment
Description: mircovascular function parameters will be measured by administering adenosine in two different pathways
Study NCT06269874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: microvascular function assessment
Description: mircovascular function parameters will be measured by administering adenosine in two different pathways
Study NCT06615310 — intervention group
Intervention type: OTHER
Intervention: ultrasonograpic evaluotion
Description: The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
Study NCT06610344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol
Description: R-1,3-Butanediol 35 mL
Study NCT06618898 — intervention group
Intervention type: OTHER
Intervention: online questionnaire
Description: The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.